Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality | Heart

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via BCS

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Article metrics

XML

Cardiac risk factors and prevention

Original article

Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality

Online download statistics by month:

Online download statistics by month: July 2016 to October 2021

	Abstract	Full	Pdf
Jul 2016	421	171	47
Aug 2016	1048	414	209
Sep 2016	301	202	77
Oct 2016	1291	243	199
Nov 2016	332	650	98
Dec 2016	184	404	191
Jan 2017	129	167	50
Feb 2017	18	105	40
Mar 2017	17	291	49
Apr 2017	10	210	41
May 2017	8	186	29
Jun 2017	27	124	30
Jul 2017	117	115	26
Aug 2017	124	99	17
Sep 2017	123	98	19
Oct 2017	93	89	21
Nov 2017	189	161	9
Dec 2017	186	147	18
Jan 2018	163	118	15
Feb 2018	189	142	15
Mar 2018	514	422	30
Apr 2018	473	459	30
May 2018	286	242	23
Jun 2018	211	193	47
Jul 2018	194	144	37
Aug 2018	257	241	20
Sep 2018	238	222	14
Oct 2018	333	311	19
Nov 2018	573	371	27
Dec 2018	368	348	16
Jan 2019	322	255	25
Feb 2019	239	217	25
Mar 2019	144	108	17
Apr 2019	138	76	24
May 2019	159	120	40
Jun 2019	99	75	24
Jul 2019	82	55	12
Aug 2019	127	101	20
Sep 2019	114	92	17
Oct 2019	105	95	10
Nov 2019	179	99	21
Dec 2019	86	76	14
Jan 2020	91	78	25
Feb 2020	141	94	20
Mar 2020	167	164	20
Apr 2020	80	74	17
May 2020	61	57	15
Jun 2020	51	40	13
Jul 2020	45	42	33
Aug 2020	314	291	22
Sep 2020	74	35	12
Oct 2020	94	52	17
Nov 2020	101	55	28
Dec 2020	91	49	10
Jan 2021	104	73	22
Feb 2021	95	63	15
Mar 2021	108	76	15
Apr 2021	235	192	22
May 2021	82	68	21
Jun 2021	59	59	19
Jul 2021	43	43	14
Aug 2021	66	66	20
Sep 2021	55	55	17
Oct 2021	92	60	32
Total	12460	10244	2141